Check for updates

OPEN ACCESS

APPROVED BY Frontiers Editorial Office, Frontiers Media SA, Switzerland

*CORRESPONDENCE Frontiers Production Office production.office@frontiersin.org

RECEIVED 10 September 2024 ACCEPTED 10 September 2024 PUBLISHED 19 September 2024

CITATION

Frontiers Production Office (2024) Erratum: First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax). *Front. Immunol.* 15:1494021. doi: 10.3389/fimmu.2024.1494021

COPYRIGHT

© 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Erratum: First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax)

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

glioblastoma, vaccine, immunotherapy, dendritic cell, adoptive cell therapy, radiochemotherapy

An erratum on

First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax)

By Ridolfi L, Gurrieri L, Riva N, Bulgarelli J, De Rosa F, Guidoboni M, Fausti V, Ranallo N, Calpona S, Tazzari M, Petrini M, Granato AM, Pancisi E, Foca F, Dall'Agata M, Bondi I, Amadori E, Cortesi P, Zani C, Ancarani V, Gamboni A, Polselli A, Pasini G, Bartolini D, Maimone G, Arpa D and Tosatto L (2024). *Front. Immunol.* 15:1404861. doi: 10.3389/fimmu.2024.1404861

Due to a production error, an author name was incorrectly spelled as "Monia D'Allagata". The correct spelling is "Monia Dall'Agata".

The publisher apologizes for this mistake.

The original version of this article has been updated.